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Background: Unlike glycolytic enzymes that directly catabolize glucose to pyruvate, the family of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFBs) control the conversion of fructose-6-phosphate to
and from fructose-2,6-bisphosphate, a key regulator of the glycolytic enzyme phosphofructokinase-1 (PFK-1). One
family member, PFKFB3, has been shown to be highly expressed and activated in human cancer cells, and
derivatives of a PFKFB3 inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), are currently being developed
in clinical trials. However, the effectiveness of drugs such as 3PO that target energetic pathways is limited by
survival pathways that can be activated by reduced ATP and nutrient uptake. One such pathway is the process of
cellular self-catabolism termed autophagy. We hypothesized that the functional glucose starvation induced by
inhibition of PFKFB3 in tumor cells would induce autophagy as a pro-survival mechanism and that inhibitors of
autophagy could increase the anti-tumor effects of PFKFB3 inhibitors.
Results: We found that selective inhibition of PFKFB3 with either siRNA transfection or 3PO in HCT-116 colon
adenocarcinoma cells caused a marked decrease in glucose uptake simultaneously with an increase in autophagy
based on LC3-II and p62 protein expression, acridine orange fluorescence of acidic vacuoles and electron microscopic
detection of autophagosomes. The induction of autophagy caused by PFKFB3 inhibition required an increase in
reactive oxygen species since N-acetyl-cysteine blocked both the conversion of LC3-I to LC3-II and the increase in
acridine orange fluorescence in acidic vesicles after exposure of HCT-116 cells to 3PO. We speculated that the induction
of autophagy might protect cells from the pro-apoptotic effects of 3PO and found that agents that disrupt autophagy,
including chloroquine, increased 3PO-induced apoptosis as measured by double staining with Annexin V and
propidium iodide in both HCT-116 cells and Lewis lung carcinoma (LLC) cells. Chloroquine also increased the
anti-growth effect of 3PO against LLCs in vivo and resulted in an increase in apoptotic cells within the tumors.
Conclusions: We conclude that PFKFB3 inhibitors suppress glucose uptake, which in turn causes an increase in
autophagy. The addition of selective inhibitors of autophagy to 3PO and its more potent derivatives may prove useful
as rational combinations for the treatment of cancer.
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Bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bispho-
sphatases (PFKFBs) regulate glycolytic flux by controlling
the steady state concentration of fructose 2,6 bisphosphate
(F2,6BP), a potent allosteric regulator of PFK-1 [1]. The
PFKFB family consists of four isoforms of which PFKFB3 is
of particular interest to the pharmaceutical industry since* Correspondence: jason.chesney@louisville.edu; sucheta.telang@louisville.edu
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reproduction in any medium, provided the orPFKFB3 mRNA and protein are increased in tumors when
compared to normal tissues [2,3]. Although the precise
mechanisms for high PFKFB3 expression in human can-
cers are not fully understood, PFKFB3 mRNA transcrip-
tion is promoted by HIF-1α [4,5] and by the progesterone
receptor [6]. Additionally, loss of the tumor suppressor
PTEN has recently been found to reduce APC/Cdh1-
mediated degradation of PFKFB3 [7] and protein kinase B
(AKT) can phosphorylate PFKFB3 resulting in activation
[8]. Importantly, deletion of the Pfkfb3 gene decreases can-
cer cell glucose metabolism and anchorage-independenttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zyme a promising target for anti-cancer therapy [9] and
molecular modeling has allowed for the development of
novel small molecule inhibitors that are able to competi-
tively inhibit PFKFB3 enzyme activity.
One such inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-
2-propen-1-one (3PO), has been found to suppress glyco-
lytic flux to lactate, decrease glucose uptake and attenuate
the proliferation of several human cancer cell lines in vitro,
including MDA-MB-231 breast adenocarcinoma cells,
K-562, HL-60 and Jurkat leukemia cells, HeLa cervical
adenocarcinoma cells, and A2058 melanoma cells [10].
Importantly, 3PO has also been found to be selectively
cytotoxic to Ras-transformed bronchial epithelial cells re-
lative to untransformed, normal bronchial epithelial cells
in vitro [10]. Last, 3PO displayed anti-metabolic and anti-
tumor effects against Lewis lung carcinoma (LLC), MDA-
MB-231 breast and HL-60 leukemic xenograft tumors
in vivo [10]. Although tumor growth was decreased by
treatment with 3PO, it was not completely suppressed,
presumably as a result of metabolic resistance mecha-
nisms [10].
Cells in limited nutrient micro-environments, such as
those with low amino acid and glucose concentrations, ac-
tivate the cellular self-digestion process termed autophagy
[11-13]. While this process occurs at a basal level within
cells playing a complementary role with the proteasome to
help clear larger and more abundant material, the induc-
tion of autophagy can be triggered by stressful stimuli such
as nutrient deprivation. Under these conditions, autophagy
is a means by which cells are able to degrade cellular com-
ponents to provide biosynthetic precursors which can be
used for anabolic processes and energy production [14-17].
The induction of autophagy may play an especially critical
role in conferring resistance to anti-metabolic drugs since
these agents induce states that mimic low nutrient envi-
ronments. For example, 2-deoxy-glucose has been shown
to induce autophagy both in vitro and in vivo as part of a
phase I clinical trial for prostate cancer [18-20].
We postulated that the metabolic stress caused by
PFKFB3 inhibition might activate autophagy as a sur-
vival pathway, which in turn might confer resistance to
3PO. Chloroquine (CQ), an anti-malarial agent that has
been used in humans since the 1940’s, has been shown
to inhibit autophagy and potentiate cancer cell death
and is now being added to a number of other drugs as a
part of several human cancer clinical trials [21-26]. We
hypothesized that the combination of the PFKFB3 in-
hibitor 3PO with the autophagy inhibitor CQ might lead
to a significant improvement in the anti-cancer effects
of 3PO in vitro and that this combination might also
increase efficacy of 3PO as an anti-tumor agent in vivo.
The results of this study demonstrate that PFKFB3




Human colorectal carcinoma cells (HCT-116) obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA) were cultured with McCoy’s 5A
medium (Gibco, Grand Island, NY, USA) supplemented
with 10% calf serum and 50 μg/mL gentamicin. LLC cells
obtained from ATCC were cultured in Dulbecco’s Modified
Eagle Medium (Gibco) supplemented with 10% calf serum
and 50 μg/mL gentamicin. Cells were incubated at 37°C
with 5% CO2.
siRNA transfection
HCT-116 cells were plated at 100,000 cells/well in a 6-well
dish in 2.5 mL complete medium and, 24 hours after seed-
ing, were transfected with either control siRNA (Stealth
Negative Control Medium GC Duplex) or PFKFB3 siRNA
(HSS107860 or HSS107862) (all from Invitrogen, Grand
Island, NY, USA). For siRNA experiments on LLC cells,
cells were transfected with control siRNA (as above) or
PFKFB3 siRNA (Silencer Select ID# s100777 Ambion/
Invitrogen). ATG5 siRNA was obtained from Invitrogen
(ATG5 HSS114103). OptiMEM (Invitrogen) with 1%
Lipofectamine RNAiMAX (Invitrogen) was incubated at
RT for 5 minutes. siRNA was added to the Lipofectamine
mixture and incubated for 20 minutes at room tempe-
rature. The mixture was added to a single well of the
6-well plate for a total volume of 3 mL and a final siRNA
concentration of 10 nM. Cells were incubated at 37°C for
48 hours before harvest. Samples in which bafilomycin A1
was used were treated with 1 nM bafilomycin A1 (Sigma,
St. Louis, MO, USA) for 24 hours prior to harvest.
Small molecules
3PO was synthesized as previously described [10]; 7,8-
dihydroxy-3-(4-hydroxyphenyl) chromen-4-one (YN1) was
obtained from Chess (Mannheim, Germany); and CQ, 3-
methyladenine, Spautin-1 and bafilomycin A1 were ob-
tained from Sigma.
Protein extraction
Cells were washed with PBS then lifted in 0.25% trypsin
(Gibco) and pelleted by centrifugation. Pellets were lysed
in protein lysis buffer (Thermo, Rockford, IL, USA) sup-
plemented with protease and phosphatase inhibitors
(Sigma). Samples were homogenized by passing repeatedly
through a 28 ½ gauge needle and then incubated on ice
for 20 minutes before centrifugation at 2,000 g for 5 mi-
nutes at 4°C and collection of supernatants. Protein con-
centration was determined using the bicinchoninic acid
assay (Thermo).
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Equal amounts of protein were added to loading buffer
(BioRad, Hercules, CA, USA) containing 50 μL/mL
β-mercaptoethanol and heated to 98°C for 5 minutes and
then loaded onto a 4–20% gradient SDS-polyacrylamide
gel (BioRad) and run for 60 minutes at 130 volts. The pro-
tein was transferred to a nitrocellulose membrane over 1
hour at 400 mA and then blocked in 5% non-fat milk for
1 hour before incubation with primary antibodies. Anti-
bodies against LC3, p62, p-p70S6K, p70S6K, pS6, S6,
phospho-AMPK, AMPK, phospho-ULK1, and ULK1 (Cell
Signaling, Danvers, MA, USA), PFKFB3 (Proteintech,
Chicago, IL, USA), and β-actin (Sigma) were diluted 1:1,000
and incubated overnight at 4°C, with the exception of p62
and β-actin Ab, which were incubated at room tem-
perature for 1 hour. Membranes were washed for 30 mi-
nutes in Tris-buffered saline with Tween 20 (TBS-T) (50
mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20)
before addition of secondary antibodies (anti-mouse or
anti-rabbit), diluted 1:10,000 in TBS-T (Sigma). ECL
Western Blotting Detection Kit (Amersham/GE Pittsburgh,
PA, USA) was used to develop membranes. Quantitative
densitometry was performed using Image J (NIH).
F2,6BP assay
Intracellular F2,6BP levels were determined using a method
previously described [27]. Briefly, HCT-116 cells were har-
vested 48 hours after transfection or after treatment with
3PO and centrifuged at 200 g. The pellets were resus-
pended in 50 mM Tris acetate (pH 8.0) and 100 mM
NaOH, incubated at 80°C for 5 minutes, and then placed
on ice. Extracts were neutralized to pH 7.2 with 1 M acetic
acid and 1 M Hepes and then incubated at 25°C for 2 mi-
nutes in 50 mM Tris, 2 mM Mg2+, 1 mM F6P, 0.15 mM
NAD, 10 U/L PPi-dependent PFK-1, 0.45 kU/L aldolase, 5
kU/L triosephosphate isomerase, and 1.7 kU/L glycerol-
3-phosphate dehydrogenase. Pyrophosphate (0.5 mM) was
added and the rate of change in absorbance (OD = 339
nm) per minute over 5 minutes was determined. A calibra-
tion curve using 0.1 to 1 pmol of F2,6BP (Sigma) was used
to calculate F2,6BP, which was then normalized to total
protein.
2-[1-14C]-deoxy-D-glucose (2DG)uptake assay
HCT-116 cells were plated at 100,000 cells/well in a 6-well
dish. Cells were transfected with either control siRNA
or siRNA directed against PFKFB3, or treated with 3PO.
Forty eight hours post-transfection or after 3PO treatment,
cells were washed with PBS and media was replaced with
glucose-free RPMI 1640 (Gibco) for 30 minutes. 2-[1-14C]-
deoxy-D-glucose (2DG) (Perkin Elmer, Waltham, MA,
USA) was added for 30 minutes. Cells were washed three
times with ice-cold RPMI 1640 containing no glucose and
then lysed with 0.1% SDS. Scintillation counts (counts/min) were measured on a portion of lysate and normalized
to protein concentration using the remainder of the lysate.
Data are represented as mean ± SD from duplicate
samples.
Acridine orange immunofluorescence
After 48 hours of transfection or after 3PO treatment,
HCT-116 cells were washed with PBS and then stained
with 0.001 mg/mL acridine orange in PBS for 15 minutes
at 37°C. Cells were washed twice with PBS, then harvested
for study by microscopy or flow cytometry. For immuno-
fluorescent examination and imaging, cells were viewed
using an EVOSfl fluorescent microscope (AMG, Grand
Island, NY, USA). Acridine orange was visualized using an
overlay of GFP and RFP filters. For flow cytometry, green
(510–530 nm) and red (650 nm) fluorescence emission
from 10,000 cells illuminated with blue (488 nm) excita-
tion light was measured (BD FACSCalibur, San Jose, CA,
USA). FlowJo software (TREE STAR Inc., San Carlos, CA,
USA) was used for analysis.
Electron microscopy
HCT-116 cells were prepared for electron microscopy
48 hours post-transfection or after treatment with 3PO.
Cells were washed twice with PBS and fixed in cold glu-
taraldehyde (3% in 0.1 M cacodylate buffer, pH 7.4) for
30 minutes. Samples were post fixed in OsO4 and 100
nm sections were taken and stained with uranyl/lead cit-
rate and viewed using a transmission electron micro-
scope (Phillips CM12). Methodology and identification
of autophagic structures was based on established cri-
teria and previous studies [28-30].
ATP measurement
ATP levels were determined using a bioluminescence assay
(Invitrogen) following established protocols from suppliers.
Briefly, cells were lysed on cultured plates using 1X passive
lysis buffer (Molecular Probes, Carlsbad, CA, USA), snap
frozen in liquid nitrogen, then thawed at 37°C and spun at
1,200 g for 30 seconds at 4°C to clear the lysates. Lysate
was added to a prepared reaction solution containing reac-
tion buffer, DTT, d-luciferin and firefly luciferase, and
luminescence was read using a luminometer (TD-20/20,
Turner Designs, Sunnyvale, CA, USA). ATP was deter-
mined based on a standard curve using 1–500 nM ATP
and was calculated relative to protein concentration.
Reactive oxygen species measurement
2’,7’-dichlorofluorescein diacetate (DCFDA) (1 nM; Invi-
trogen) was diluted in 1X PBS containing magnesium and
calcium (Gibco) and added to washed cells and incubated
at 37°C for 30 minutes before being analyzed by flow cy-
tometry (BD FACSCalibur). Data was analyzed using
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as the average of triplicate samples ± SD.
Apoptosis assay
Cells were stained with annexin-V labeled with FITC and
propidium iodide (PI) following the manufacturer’s proto-
col (BD Biosciences, San Diego, CA, USA). Briefly, cells
were lifted and pelleted by centrifugation at 2,500 rpm for
5 minutes. Cell pellets were washed with 1X PBS and
100,000 cells were pelleted by centrifugation at 2,500 rpm
for 5 minutes. Pellets were resuspended in 1X Binding
Buffer and annexin-V/FITC and/or PI was added and cells
were incubated in the dark at room temperature for 10 mi-
nutes. 1X Binding Buffer was added to increase the volume
and 10,000 events were counted for each sample using
the appropriate filters for FITC and PI detection (BD
FACSCalibur). Data was analyzed using FlowJo software
(TREE STAR Inc.). Results were calculated as the average
of triplicate samples ± SD.
Tumor model
Twelve-week-old female C57/BL6 mice were injected
subcutaneously with 1×106 LLC cells and once tumors
reached 150–200 mg, mice were randomized into four
groups (n = 6 per group): Group 1, Vehicle (DMSO +
PBS); Group 2, Chloroquine (DMSO + 50 mg/kg CQ);
Group 3, 3PO (0.07 mg/g 3PO + PBS); Group 4, (0.07
mg/g 3PO + 50 mg/kg CQ). Drug treatments were based
on published tumor models [10,31,32]. Mice were given
daily intraperitoneal injections with either vehicle or
drug and tumors were measured using microcalipers for
estimation of tumor volume. At the conclusion of the
study, mice were euthanized and tumors were removed.
Tumor tissues were fixed in paraformaldehyde and pre-
pared for immunohistochemistry. Animal experiments
were carried out in accordance with established practices
as described in the National Institutes of Health Guide
for Care and Use of Laboratory Animals and were
approved by the University of Louisville Institutional
Animal Care and Use Committee.
Immunohistochemistry
Tumors excised after completion of tumor measurements
were fixed in paraformaldehyde for 24 hours and then em-
bedded in paraffin, sectioned and stained with an anti-
cleaved caspase 3 antibody (1:200, Cell Signaling, Danvers,
MA, USA) using standard immunohistochemical methods.
Results
Transfection of HCT-116 cells with PFKFB3 siRNA
suppresses glucose uptake and increases reactive
oxygen species
PFKFB3 expression is high in colon adenocarcinomas and
we thus initially transfected HCT-116 colon adenocarcinomacells with PFKFB3-specific siRNA and confirmed selective
suppression of PFKFB3 relative to cells transfected with a
control siRNA (Figure 1A, B). Knockdown of PFKFB3
with either PFKFB3-targeted siRNA resulted in a marked
reduction in the steady-state concentration of its product,
F2,6BP, 48 hours after siRNA transfection (Figure 1C) and
decreased cell proliferation (viable cells [× 104/mL]: 24
hours, control, 89 ± 4 and PFKFB3 siRNA, 68.3 ± 3.5; 48
hours, control, 187 ± 8.5 and PFKFB3 siRNA, 78.9 ± 5.4;
72 hours, control, 289.9 ± 8.5 and PFKFB3 siRNA, 85.6 ±
6.3; P <0.05 for all time points). Decreased F2,6BP will
inhibit PFK-1 activity, which results in an increase of
the PFK-1 substrate fructose-6-phosphate (F6P). F6P is in
equilibrium with glucose-6-phosphate, an allosteric inhi-
bitor of hexokinase, which itself is required for glucose
uptake [33-35]. Accordingly, we suspected that reduced
PFK-1 activity caused by PFKFB3 siRNA would suppress
glucose uptake as has been observed after deletion of the
Pfkfb3 gene [9]. To measure glucose uptake, 2DG was in-
cubated with cells transfected with the siRNA species -
2DG uptake was reduced by more than 50% after 48
hours in the PFKFB3 siRNA-transfected HCT-116 cells
(Figure 1D). These data suggest that PFKFB3 inhibition
causes a functional deprivation of glucose similar to that
seen in a glucose-poor environment. Importantly, glucose
deprivation results in reduction of the mTOR effector
ribosomal protein S6 [36] and intracellular ATP [37], and
causes an increase in reactive oxygen species (ROS) [38].
The increase in ROS is presumably as a result of decreased
mitochondrial membrane potential and depletion of glu-
tathione as previously reported [38,39] or, alternatively,
suppression of glycosylation which is also known to result
in increased ROS [40]. As has been observed by glucose
deprivation, we found that PFKFB3 inhibition reduced
intracellular ATP (Figure 1G), increased phosphorylation
of both AMPK and ULK1 (Figure 1E, F), inhibited phos-
phorylation of p70 S6 kinase (p70S6K) and ribosomal pro-
tein S6 (S6) (Figure 1E, F), and increased ROS (Figure 1H).
Each of these findings is consistent with the concept that
PFKFB3 inhibition mimics a glucose-poor environment.
PFKFB3 knockdown results in activation of autophagy
Glucose starvation induces autophagy and suppression of
S6 or ATP and/or an increase in ROS can each result in
an increase in autophagy [41,42]. We thus sought to deter-
mine if the decrease in glucose uptake due to knockdown
of PFKFB3 similarly increased autophagy in HCT-116
cells. Transfection of HCT-116 cells with PFKFB3 siRNA
resulted in a significant increase in the microtubule-
associated protein 1 light chain 3-II (LC3-II), which is a
component of the autophagosomal membrane that is
increased during autophagy (Figure 2A, B). Importantly,
bafilomycin A1, a vacuolar type H+-ATPase that inhibits
lysosomal function and is used to block LC3-II degradation,
Figure 1 Transfection of HCT-116 cells with PFKFB3 siRNA inhibits F2,6BP, glucose uptake, ATP and S6K/S6 phosphorylation and
simultaneously increases ROS. HCT-116 cells were transfected with either a control siRNA (ctrl) or 10 nM of a siRNA directed against PFKFB3
(PFKFB3). Total protein was harvested 48 hours post-transfection and protein levels relative to β-actin were determined by Western blotting (A).
Densitometry data are presented as the mean fold change ± SD from three experiments (B). F2,6BP levels were determined using an
enzyme-coupled assay (C). Glucose uptake was estimated based on the uptake of 2DG (D). After 48 hours of transfection with either a control or
a PFKFB3-specific siRNA, protein expression of both phosphorylated and total levels of downstream mTOR targets, p70S6K and ribosomal protein
S6 (S6) and of AMPK and ULK1 were measured using Western blotting (E). Quantitative densitometry is reported as phosphorylated protein relative
to total protein for p70S6K, S6, AMPK and ULK1 (F). ATP was measured using a bioluminescence assay (G) and reactive oxygen species were measured
after loading the cells with DCFDA using flow cytometry (H). Data are presented as the mean fold change ± SD of three experiments (*P <0.05).
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tophagic flux is increased rather than a block in LC3-II
degradation (Figure 2A, B) [43,44]. An additional indicator
of autophagy, p62, a ubiquitin-binding scaffold protein
that plays a role in the targeting of cargo to autophago-
somes where it is degraded, was found to be decreased by
PFKFB3 siRNA transfection further supporting an in-
crease in autophagy (Figure 2A, C) [45].
Acridine orange, a cell-permeable fluorescent dye, be-
comes protonated and trapped in acidic compartments
such as lysosomes that are increased in autophagy and,
upon excitation (488 nM), emits a red light (650 nM).
HCT-116 cells transfected with PFKFB3 siRNA had a
significantly higher emission of red light when viewed
by fluorescent microscopy (data not shown) and PFKFB3
knockdown also resulted in a shift in FL-3 (red) fluores-
cence by flow cytometry, indicating that the PFKFB3-
siRNA transfected cells had a larger quantity of acidic
compartments, a characteristic of cells with increased au-
tophagic activity (Figure 2D). Since this is the first demon-
stration that selective PFKFB3 inhibition causes an
induction of autophagy, we also transfected the HCT-116
cells with a second PFKFB3-specific siRNA (see Methods)
and confirmed an increase in LC3-II by Western blot ana-
lyses and in acridine orange high cells by flow cytometry
(Additional file 1: Figure S1).
Another technique commonly used to confirm the
process of autophagy is electron microscopy. HCT-116cells were transfected with PFKFB3 siRNA or a negative
control siRNA and, 48 hours post-transfection, were col-
lected and analyzed using a Phillips CM12 transmission
electron microscope. An increase in intracellular struc-
tures including double-membrane bound vesicles con-
sistent with autophagosomes was observed only in cells
transfected with PFKFB3 siRNA (Figure 2E) [46].
Small molecule inhibition of PFKFB3 decreases glucose
uptake and increases ROS
A small molecule designed to target the F6P binding site
of the PFKFB3 enzyme, 3PO, has previously been shown
to inhibit recombinant PFKFB3 activity and decrease
glucose uptake and F2,6BP [10]. To validate this small
molecule in our model system, we first examined the ef-
fect of 3PO on the proliferation of HCT-116 cells and
found a dose dependent inhibition of growth (viable cells
[× 104/mL]: 24 hours, control, 21 ± 1.7 and +15 μM
3PO, 4.67 ± 1.2; 48 hours: control, 32.8 ± 0.95 and +15
μM 3PO, 10.2 ± 1.53; 72 hours: control, 39.63 ± 1.7
and +15 μM 3PO, 10.45 ± 1.1; P <0.05 for all time points).
HCT-116 cells then were treated with either vehicle alone
or 10 μM 3PO and F2,6BP levels and glucose uptake were
measured. A sharp drop in F2,6BP and glucose uptake was
noted after only 2 hours of 3PO exposure (Figure 3A, B).
Similar to the PFKFB3 siRNA, we observed an increase in
ROS (2 and 8 hours; Figure 3C), and decrease in ATP (24
hours; Figure 3D) and S6 kinase and S6 phosphorylation
Figure 2 Transfection of HCT-116 cells with PFKFB3 siRNA stimulates autophagy. LC3-II and p62 protein levels were determined using
Western blotting 48 hours after transfection with either control (ctrl) or a siRNA directed against PFKFB3 (PFKFB3) (A). Treatment with 1 nM
bafilomycin A1 (Baf A1) was used to determine if LC3-II levels were a result of increased autophagic flux or impaired degradation (A). Quantitative
densitometry was performed to assess relative protein levels (B, C). LC3-II and p62 levels are expressed as the mean fold change ± SD from three
experiments relative to LC3-I or β-actin and control. After 48 hours of transfection with either control (ctrl) or PFKFB3-specific siRNA, cells also
were stained with acridine orange, observed by fluorescent microscopy and collected by flow cytometry to measure the relative content of acidic
compartments (D). Examination of the cells by electron microscopy demonstrated that PFKFB3 siRNA transfection resulted in cells containing
intracellular structures consistent with autophagosomes (E; arrow). Data are presented as the mean ± SD from three experiments (*P <0.05).
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siRNA data, these results indicate that selective inhibition
of PFKFB3 results in several biochemical changes that
occur as a result of the glucose starvation state and that
are known to activate autophagy.
Small molecule inhibition of PFKFB3 induces autophagy
Like PFKFB3 knockdown, the autophagy marker LC3-II
was increased by 3PO and the induction was due to in-
creased synthesis rather than a blockade of protein degrad-
ation as indicated by the further increase in LC3-II upon
addition of bafilomycin A1 (Figure 4A, B). Also similar to
the PFKFB3 siRNA, 3PO resulted in a dose-dependent de-
crease in p62 (Figure 4A, C) and increased acridine orangeimmunofluorescence which was visualized by fluorescent
microscopy (data not shown) and quantified using flow cy-
tometry (Figure 4D, E). Last, after 24 hours of 10 μM 3PO
exposure, HCT-116 cells were noted to have numerous
intracellular structures consistent with autophagosomes,
visualized by electron microscopy (Figure 4F). We con-
firmed our findings by examining the effects of a second
small molecule inhibitor of PFKFB3, YN1, on HCT-116
cells [47]. Cells treated with two concentrations of YN1 or
vehicle for 48 hours were counted, F2,6BP levels were
measured and were then examined for LC3-II and p62.
Similar to 3PO, YN1 decreased viable cell counts, F2,6BP
and led to a dose-dependent increase in LC3-II and a
decrease in p62 (Additional file 2: Figure S2).
Figure 3 Small molecule inhibition of PFKFB3 decreases glucose uptake and increases ROS in HCT-116 cells. HCT-116 cells were treated
with 10 μM 3PO and cells were harvested at the indicated time points for the measurement of F2,6BP using an enzyme- coupled assay (A), 2DG
uptake (B), ROS by DCFDA staining (C), ATP (D), and phospho-p70S6K, p70S6K, phospho-S6, S6, and β-actin by Western blot (E) and densitometry
(F). Data are presented as the mean ± SD from three experiments (*P <0.05).
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reversed with N-acetylcysteine
ROS have been found to stimulate autophagy in part
through the mTOR pathway [42]. The observed correl-
ation between oxidative stress and autophagy was further
examined using the anti-oxidant N-acetylcysteine (NAC),
which can act as a precursor to the antioxidant glutathi-
one. NAC partially blocked the increase in ROS induced
by 3PO, as determined by flow cytometric measurement
of DCFDA fluorescence (Figure 5A, D). The reduction
in ROS following 3PO treatment caused by NAC also
blocked the induction of autophagy as measured by loss of
LC3-II (Figure 5B, C) and a reduction in acridine orange
immunofluorescence (Figure 5E, F). Although these data
suggest that the observed increase in autophagy caused
by 3PO is dependent on an increase in ROS caused by
PFKFB3 inhibition, the high concentration of NAC that
was used (1 mM) may have non-specific effects on autoph-
agy as well as on the cytostatic effects of 3PO. Importantly,
given the effects of PFKFB3 inhibition on mTOR signaling,
AMPK phosphorylation and ROS, we suspect that the
induction of autophagy observed after PFKFB3 inhibition
is due to multiple indirect and direct mechanisms.
Pharmacologic inhibition of autophagy in combination
with 3PO increases tumor cell death
In order to determine if autophagy following 3PO treat-
ment serves as a survival mechanism, we assessed whetherCQ, an agent that accumulates in lysosomes and interferes
with autophagy, would promote or inhibit the cytotoxic
effects of 3PO. Although exposure to 3PO alone caused a
modest increase in late apoptotic (PI+/annexin-V+) HCT-
116 cells, the addition of two non-toxic doses of CQ (15
or 30 μM) caused a dose-dependent increase in late apop-
totic cells (Figure 6A, B). We also found that 30 μM CQ
in combination with PFKFB3-specific siRNA transfec-
tion caused an increase in late apoptotic HCT-116 cells
(Figure 6C, D). Two additional inhibitors of autophagy
were then used in combination with 3PO in order to
confirm that suppression of autophagy promotes 3PO-
induced cell death. 3-methyladenine, an inhibitor of type
III phosphatidylinositol 3-kinases which blocks the forma-
tion of autophagosomes, and Spautin-1, which inhibits au-
tophagy by promoting increased proteasomal degradation
of class III PI3 kinase complexes through inhibition of
ubiquitin-specific peptidases USP10 and USP13, were both
found to promote the pro-apoptotic effects of 10 μM 3PO
(Figure 7A-D). In addition, we sought to examine the
effect of siRNA-mediated suppression of autophagy on
treatment with 3PO and chose to target ATG5, which is
critical for the formation of the autophagosome [48]. We
transfected HCT-116 cells with control siRNA or siRNA
targeted to ATG5, followed by 24 hours of treatment with
10 μM 3PO and then examined the cells for apoptosis.
We found that knockdown of ATG5 in the presence of
3PO caused a statistically significant increase in apoptotic
Figure 4 PFKFB3 inhibition with 3PO stimulates autophagy. HCT-116 cells were treated with either vehicle, or 7.5, 10, or 15 μM 3PO for 24
hours and LC3-II and p62 expression was measured by Western blot (A) and densitometry (B, C). Addition of bafilomycin A1 (Baf A1) was used
to determine if the changes in LC3-II were the result of increased synthesis or impaired degradation. LC3-II quantitation is relative to control +
bafilomycin due to the absence of a visible band in the control sample. HCT-116 cells were also stained with 1 μg/mL acridine orange for
15 minutes, viewed using a fluorescent microscope, harvested for flow cytometry and gating was used to quantitate the number of cells with
a high AO fluorescence and expressed relative to vehicle (D, E). Using electron microscopy, autophagic structures were seen in cells exposed
to 3PO (F; arrow).
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5,100 ± 560; control siRNA + 10 μM 3PO, 6,800 ± 590
and ATG5 siRNA + 10 μM 3PO, 12,880 ± 630, P <0.05).
CQ sensitizes Lewis Lung Carcinoma (LLC) cells to 3PO
in vitro and in vivo
We next transfected LLC cells with either control or
PFKFB3-targeted siRNA followed by treatment with 0, 15
or 30 μM CQ and found that, similar to our findings in
HCT-116 cells (Figure 6C, D), apoptosis was increased in
the LLC cells treated with PFKFB3 siRNA and 30 μM CQ
(PI+/annexin-V+ cells: control siRNA + vehicle, 4,200 ±
784; control siRNA + 30 μM CQ, 5,300 ± 890 and PFKFB3
siRNA + 30 μM CQ, 10,560 ± 1,630; P <0.05). We then
exposed LLC cells to 25 μM 3PO and observed increased
levels of LC3-II relative to control. This increase was fur-
ther enhanced upon the addition of bafilomycin A1, which
is consistent with increased autophagic flux (Figure 8A, B).Similar to the HCT-116 cells, LLC cell apoptosis caused
by 3PO was increased by CQ (Figure 8C, E). Twelve-week-
old female C57/BL6 mice then were injected subcuta-
neously with 1×106 LLC cells and, when tumors reached
150–200 mm3, were randomized into four treatment
groups (n = 6 per group): Group 1, vehicle (DMSO + PBS);
Group 2, CQ (DMSO + 50 mg/kg CQ); Group 3, 3PO
(0.07 mg/g 3PO + PBS); Group 4, CQ + 3PO (0.07 mg/g
3PO + 50 mg/kg CQ). Daily tumor measurements were
obtained using micro-calipers and the experiment was
concluded two weeks from the start of treatment. The
tumor mass was significantly reduced in animals treated
with both 3PO and CQ relative to either drug treatment
alone (Figure 8D). Importantly, the mice did not exhibit
any signs of increased toxicity including loss of body mass
or gross pathological abnormalities of several organs. Ex-
cised tumors then were stained with an antibody recogniz-
ing cleaved caspase-3, a key protein in the execution
Figure 5 N-acetylcysteine prevents 3PO-induced ROS and autophagy. HCT-116 cells were treated with either vehicle or 10 μM 3PO ± 1 mM
NAC and harvested after 8 hours of treatment for measurement of DCFDA fluorescence using flow cytometry (A, D). Cell lysates also were
prepared and LC3-II levels were determined using immunoblotting (B) and densitometry (C). Last, HCT-116 cells were stained with 1 μg/mL
acridine orange for 15 minutes and acridine orange fluorescence was determined using flow cytometry (E, F). Data are presented as the
mean ± SD from three experiments (*P <0.05).
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combination of 3PO and chloroquine were noted to have
an increased number of cleaved caspase-3 positive cells
relative to tumors from animals treated with either drug
alone (Figures 8F, G).Figure 6 Chloroquine increases the number of late apoptotic cells ca
Annexin-V/PI staining was performed in cells treated with vehicle, 3PO, CQ
staining was performed using flow cytometry (A) and the number of cells
as the percentage relative to control ± SD from three experiments (B). HCT
or with a PFKFB3-specific siRNA ± 30 μM CQ. After 48 hours of transfection
cytometry (C). Quantitation of cells staining positive for annexin-V and PI w
from three experiments (D) (*P <0.05).Discussion
The metabolic stress caused by reduced glucose avail-
ability results in a number of cellular defense mecha-
nisms critical to survive transitory periods of starvation.
For example, energy-requiring processes are suppressedused by exposure to 3PO or PFKFB3 siRNA transfection.
, or the combination of 3PO and CQ for 48 hours. Quantitation of cell
staining with both annexin-V and PI was quantitated and is expressed
-116 cells also were transfected with either a negative control siRNA
, cells were stained with annexin-V and PI and measured using flow
as performed relative to control and is expressed as the mean ± SD
Figure 7 The autophagy inhibitors, 3-methyladenine and Spautin-1, increase the pro-apoptotic effects of 3PO. HCT-116 cells were treated
with either vehicle or 7.5 μM or 10 μM 3PO ± 1 mM 3-methyladenine (3MA). Forty eight hours after treatment, cells were stained with annexin-V
and PI and measured using flow cytometry (A). Cell death was quantitated as the percentage of cells staining positive for annexin-V and PI
relative to control ± SD from three experiments (B). HCT-116 cells then were treated with either vehicle, 7.5 or 10 μM 3PO ± 15 μM Spautin-1
and, 48 hours after treatment, cells were stained with annexin-V and PI and collected by flow cytometry (C). The percentage of cells stained
positive for both annexin-V and PI was quantitated and is expressed relative to control ± SD from three experiments (D) (*P <0.05).
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activity of translational machinery and halting the cell
cycle [49-51]. At the same time, catabolic processes, such
as autophagy, are used to recycle intracellular components
in order to provide metabolic substrates which can then
be used to generate energy as well as to remove potentially
harmful intracellular material such as damaged mitochon-
dria [14,17,52-54].
In this study, we report that inhibition of PFKFB3 in
HCT-116 cells increases the lipidated form of the autop-
hagosomal membrane protein LC3 and decreases the
cargo protein p62. LC3 is cleaved to LC3-I which liberates
a C-terminal glycine that allows the conjugation to phos-
phatidylethanolamine whereupon the modified protein,
called LC3-II, can target the autophagosomal membrane.
Although counterintuitive, the heavier LC3-II migrates
faster than LC3-I due to its hydrophobicity, and is seen as
the lower band in Western blotting (Figures 2A, 4A, and
8A) [55,56]. Increased LC3-II can indicate either increased
autophagic synthesis or reduced autophagic degradation.
The addition of bafilomycin A1, an inhibitor of the vacu-
olar type H+-ATPase, allows for the determination of au-
tophagic flux by inhibiting lysosomal acidification andblocking degradation of LC3-II [55,57,58]. The further in-
crease in LC3-II protein that we observed in the presence
of bafilomycin A1 after PFKFB3 inhibition indicated that
PFKFB3 inhibition induced autophagy rather than blocked
LC3-II degradation. Importantly, PFKFB3 inhibition also
resulted in decreased p62 protein levels, an autophagy
cargo receptor protein that contains an LC3-interacting
region that targets it and its cargo to the autophagosome.
In autophagy-competent cells, this cargo protein is de-
graded along with autophagosomal contents resulting in
decreased total p62 [59]. Additionally, PFKFB3 inhibition
resulted in cells with a higher volume of acidic compart-
ments as measured using acridine orange staining, consist-
ent with increased autophagy and, when visualized by
electron microscopy, PFKFB3 inhibition also resulted in
the appearance of autophagosomal structures. Taken to-
gether, these data are the first to demonstrate that PFKFB3
inhibition causes a compensatory increase in autophagy.
Last, PFKFB3 inhibition resulted in decreased ATP,
phospho-p70S6K, and phospho-S6 and an accumulation
of ROS similar to that observed by glucose deprivation
[36-39,60,61]. Each of these biochemical events can in-
crease autophagy [41,42] and the increase in ROS mediated
Figure 8 Chloroquine increases the pro-apoptotic effects of 3PO against LLC cells and tumors in vitro and in vivo. LLC cells were treated
with 25 μM 3PO for 24 hours and LC3-II levels were measured using immunoblotting (A) and quantitative densitometry (B). Levels expressed as
mean fold change LC3-II/β-actin relative to control ± SD (B). LLC cells were then treated with either vehicle or 10 or 25 μM 3PO ± either 15 or
30 μM CQ. After 24 hours of treatment, cells were stained with annexin-V and PI and measured using flow cytometry (C). Cells staining positive
for both annexin-V and PI were quantitated as the percentage of the total relative to control and data is presented as the mean ± SD from three
experiments (E). C57/BL6 mice were inoculated with 1x106 LLC cells by subcutaneous flank injection. Mice were randomized into four treatment
groups when tumors reached 150–200 mm3 and were treated by i.p. injections with either vehicle, 50 mg/kg CQ, 0.07 mg/g 3PO, or a
combination of the two drugs. Tumor measurements taken over the course of treatment were used to calculate tumor mass. Data is presented
as mean tumor mass ± SD (D). Tumors were fixed, paraffin embedded, and stained with an antibody directed against cleaved caspase-3 (CC3)
(F). The number of cells staining positive for CC3 in five 200X fields were counted and the data is expressed as the mean ± SD from three counts
(G) (*P <0.05).
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http://www.cancerandmetabolism.com/content/2/1/2by 3PO was found to be essential for the induction of au-
tophagy since N-acetylcysteine reversed the stimulation of
autophagy caused by 3PO.
The identification of autophagy as a resistance mech-
anism utilized by tumor cells to avoid destruction andthe induction of autophagy caused by PFKFB3 inhibition
led us to postulate that the addition of autophagy inhibi-
tors to a PFKFB3 small molecule antagonist would yield
improved cytotoxic effects. In this report, we show that
cell death following treatment with the PFKFB3 inhibitor
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tors CQ, 3-methyladenine or Spautin-1. Additionally, the
combination of 3PO and CQ resulted in significantly
smaller tumors relative to either drug treatment alone. Al-
though our model system was different, the tumors from
animals treated with CQ alone failed to show any differ-
ence in tumor size, contrasting with other published tumor
studies [62,63]. Tumors that were removed from animals
at the conclusion of the study were fixed and stained with
a marker of apoptosis, cleaved caspase-3. This marker was
increased in tumors excised from animals treated with the
combination of CQ and 3PO relative to those from ani-
mals treated with either drug alone. The smaller tumor
size and increased cleaved caspase-3 staining supports the
idea that autophagy is serving as a protective mechanism
following PFKFB3 inhibition and that the efficacy of
PFKFB3 inhibitors as anti-cancer agents may be im-
proved using autophagy inhibitors such as CQ.
Conclusions
Harnessing the molecular information gained from study-
ing cancer cells over the past century in order to determine
the characteristics that distinguish them from normal cells
is paramount to developing cancer-specific therapeutics.
PFKFB3 inhibitors effectively and specifically target tumor
cells in vitro and decrease tumor burden in vivo [10]. Im-
portantly, a synthetic derivative of 3PO, termed PFK158,
has undergone investigational new drug (IND)-enabling
toxicology studies for the FDA and a Phase I clinical trial
of its efficacy in advanced cancer patients is due to be initi-
ated in early 2014 [64]. However, like so many chemo-
therapeutic agents, it is expected that resistance to these
inhibitors will be encountered in clinical trials. Elucidating
the specific resistance mechanisms triggered by targeted
therapies allows for the selection of drug combinations
that might work to combat such resistance with the hope
of increasing efficacy. In this work, we show that autoph-
agy is induced by PFKFB3 inhibition and that this induc-
tion is likely serving as a resistance mechanism given the
observed increase in apoptosis in vitro and decrease in
tumor growth in vivo mediated by pharmacologic inhibi-
tors of autophagy. In conclusion, this study supports the
further pre-clinical testing of rational combinations of
PFKFB3 inhibitors with autophagy inhibitors for toxicity
and efficacy in tumor-bearing animals.
Additional files
Additional file 1: Figure S1. Transfection of HCT-116 cells with two
separate PFKFB3-specific siRNA molecules induces autophagy. PFKFB3
and LC3-II protein levels were determined using Western blotting
48 hours after transfection with control (Ctrl) or two separate siRNA
molecules directed against PFKFB3 (PFKFB3-1, PFKFB3-2) (A). After
48 hours of transfection, HCT-116 cells were also stained with acridine
orange, observed by fluorescent microscopy and collected by flowcytometry to measure the relative content of acidic compartments (B,C).
Data are presented as the mean ± SD from three experiments (P <0.05).
Additional file 2: Figure S2. PFKFB3 inhibition with YN1 stimulates
autophagy. HCT-116 cells were treated with either vehicle or 25 or 75 μM
YN1 for 48 hours. F2,6BP concentration was measured (A), viable cells
were enumerated (B), and LC3-II and p62 expression was measured by
Western blot (C) and quantified by densitometry (D). Data are presented
as the mean ± SD from three experiments (P <0.05).
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